摩根大通发表研究报告指，首予科伦博泰生物-B(06990.HK) “增持”评级，目标价240元。科伦博泰生物成立于2016年，目前，其在中国市场拥有一款抗体药物偶联物(ADC) SKB264，并且有八个ADC正在进行临床测试中，另有三个非ADC癌症药物正在中国的新药申请(NDA)审批之中。
摩通续提到，默沙东(MRK.US) 拥有SKB264在大中华区以外的开发、使用、制造及商业化权利，并启动了10项SKB264的全球第三阶段试验，涵盖的适应症比竞争对手更广泛。因此，该行估计SKB264在中国的潜在销售高峰或逾80亿元人民币，而在中国以外的销售高峰可达到60亿美元。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-16 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.